

Human LOX1 Protein

Cat. No. LOX-HM101

Description

Source	Recombinant Human LOX1 Protein is expressed from HEK293 with His tag at the N-Terminus. It contains Ser61-Gln273.
Accession	P78380-1
Molecular Weight	The protein has a predicted MW of 25.4 kDa. Due to glycosylation, the protein migrates to 30-36 kDa under reduced condition and 60-70 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL. LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis.

Assay Data


Tris-Bis PAGE



Human LOX1 on Tris-Bis PAGE under reduced condition and Non reducing (N) condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human LOX1 is greater than 95% as determined by SEC-HPLC.